1. Home
  2. DLB vs APLS Comparison

DLB vs APLS Comparison

Compare DLB & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dolby Laboratories

DLB

Dolby Laboratories

HOLD

Current Price

$63.93

Market Cap

5.8B

Sector

Miscellaneous

ML Signal

HOLD

Logo Apellis Pharmaceuticals Inc.

APLS

Apellis Pharmaceuticals Inc.

HOLD

Current Price

$40.94

Market Cap

5.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLB
APLS
Founded
1965
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.2B
IPO Year
2004
2015

Fundamental Metrics

Financial Performance
Metric
DLB
APLS
Price
$63.93
$40.94
Analyst Decision
Strong Buy
Hold
Analyst Count
4
21
Target Price
$90.75
$33.59
AVG Volume (30 Days)
459.3K
9.1M
Earning Date
04-30-2026
05-04-2026
Dividend Yield
2.25%
N/A
EPS Growth
N/A
112.50
EPS
0.55
0.20
Revenue
N/A
$1,003,782,000.00
Revenue This Year
$6.22
N/A
Revenue Next Year
$3.84
$18.19
P/E Ratio
$116.35
$204.63
Revenue Growth
N/A
28.46
52 Week Low
$57.62
$16.10
52 Week High
$78.28
$40.95

Technical Indicators

Market Signals
Indicator
DLB
APLS
Relative Strength Index (RSI) 56.98 87.20
Support Level $63.91 $19.29
Resistance Level $64.87 $40.95
Average True Range (ATR) 1.23 0.08
MACD 0.26 -0.53
Stochastic Oscillator 71.17 96.77

Price Performance

Historical Comparison
DLB
APLS

About DLB Dolby Laboratories

Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.

About APLS Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).

Share on Social Networks: